Rilzibrutinib induced rapid and durable clinical activity in previously treated patients with immune thrombocytopenia, according to results of a phase 1/phase 2 clinical trial published in The New England Journal of Medicine.
Additionally, the oral Bruton tyrosine kinase inhibitor demonstrated a low-grade safety profile.
“Prior research with ibrutinib [Imbruvica; Pharmacyclics, Janssen] had shown that patients with chronic lymphocytic leukemia and immune thrombocytopenia [ITP] had improvement in their ITP, suggesting that Bruton tyrosine kinase [BTK] inhibition might play a role in ITP